Index

Page numbers in italics denote figures, those in bold denote tables.

acarbose 100
ACCORD trial 91, 96, 98, 103, 126, 133
acetoacetate 8, 11
acetone 8, 11
acidosis
  hyperchloremic 25, 26, 42
  hypochloremic 12, 26, 27
lactic acidosis 34, 133–47
  metabolic see metabolic acidosis
  paradoxical 22
ACTH, increased secretion 86
adolescents
  diabetic ketoacidosis 33–60
    see also diabetic ketoacidosis
  obesity in 35–6
ADOPT trial 120
adrenaline see epinephrine
ADVANCE trial 91
alcoholic ketoacidosis 14
American Diabetes Association 34
amylose 68
  in DKA 13, 37
anion gap
  in alcoholic ketoacidosis 14
  calculation of 143
  in DKA 2, 10–11, 25, 69
  in lactic acidosis 140–1
  metabolic acidosis 143–4
  normal 11, 143
antidiabetic agents see insulin
  secretagogues; oral
  antidiabetic agents
arterial pH
  in DKA 2, 14, 22, 28, 30, 47, 62
  in lactic acidosis 140, 141
ATP 134, 135
atypical diabetes see ketosis-prone diabetes
bicarbonate
  in acidosis correction 21–2, 29, 47
  levels in DKA 2, 11, 45, 55
  levels in HHS 61, 79
  levels in lactic acidosis 141
biguanides 157
  and lactic acidosis 137
calcium, in DKA 12
Carbicarb 141, 142
carbohydrates, in hypoglycemia 98, 100, 125
case studies
  diabetic ketoacidosis 28–30
  HHS 79–82
  hyperglycemia
    in-hospital 171–5
    perioperative hyperglycemia 171–5

© 2011 John Wiley & Sons, Ltd. Published 2011 by John Wiley & Sons, Ltd.
hypoglycemia 105–9, 127–30
illness in diabetics 187–90
lactic acidosis 142–6
catecholamines 33, 68, 136
see also epinephrine; norepinephrine
cerebral edema 25–6, 48–51, 76–7
diagnosis 50, 76
risk factors 49
treatment 50–1, 76–7
Cheyne-Stokes respiration 26, 50
children
diabetic ketoacidosis 33–60
see also diabetic ketoacidosis
nocturnal enuresis 180
obesity 35–6
chloride
losses 12, 43
replacement 22, 43
see also hyperchloremic acidosis; hypochloremic acidosis
chlorpropamide 113, 114, 115
hypoglycemia caused by 118, 119
intolerance to alcohol 115
colloids 15, 24, 42
common cold 190
consciousness, level of 38, 38
cortisol 33, 165
hypoglycemia response 121
counter-regulatory response
aging effect 122
hormones involved in 33, 121–2, 121
type 1 diabetes 86, 87–9
type 2 diabetes 121–2, 121
creatine kinase 77, 141
crystalloids 42
DARTS-MEMO database 92
dead-in-bed syndrome 96
dehydration
assessment 38–9
in DKA 7, 9
in HHS 61
treatment 15, 17, 17
see also fluid replacement
Diabetes Control and Complications Trial 91
diabetes mellitus
DKA see diabetic ketoacidosis
ketosis-prone 1, 3
type 1 3–4
counter-regulatory response
86, 87–9
hypoglycemia in see insulin-induced hypoglycemia
ketoacidosis see diabetic ketoacidosis
perioperative hyperglycemia 165–6
type 2 3–4
and childhood obesity 35–6
clinical trials 91
counter-regulatory response
121–2, 121
HHS in 62
hypoglycemia in see insulin secretagogue-induced hypoglycemia
insulin resistance 72
and lactic acidosis 137
perioperative hyperglycemia 165–6
diabetic ketoacidosis (DKA) 1–32, 149, 178
case studies 28–30
children and adolescents 33–60
case study 54–7
causes 34–6
complications 48–53
diagnosis 37
epidemiology 36–7, 36
management 35, 40–8
monitoring 35, 40
prevention 51–3, 52
classification 2–4, 2
clinical presentation 9–10
complications 25–7, 48–53
definition 2–4
diagnostic criteria 2
differential diagnosis 14
etiology 33
laboratory findings 10–13, 12, 39
electrolyte losses 7, 11–12, 12, 34, 43
hyperglycemia 3, 7, 11–12
leukocytosis 12–13
serum osmolality 2, 13
management 15–23, 16
children and adolescents 40–8
electrolyte replacement 22–3, 43, 46–7
fluid replacement 15, 17, 17, 41–2, 43–4
insulin therapy 17–21, 42, 45–6, 47–8
transition to oral fluids 47–8
treatment of acidosis 21–2
mortality 1
pathogenesis 6–9, 6
hyperglycemia 3, 7
ketonemia and metabolic acidosis 2, 8–9
patient advice 53–4
patient monitoring 23–5, 24, 25
predisposing factors 4–6
prevention 27, 51–3, 52
supportive measures 39–40
see also hyperglycemia
diabetes and vomiting 187–8
diazoxide 64, 125, 126
dichloroacetate 142
dipeptidyl-peptidase inhibitors 124
DKA see diabetic ketoacidosis

Edinburgh Hypoglycemia Scale 93, 94
electrolyte loss 149
in DKA 7, 11–12, 12, 34, 43
in HHS 12
electrolyte replacement 22–3
epinephrine 33
hypoglycemia response
type 1 diabetes 86
type 2 diabetes 121
European Agency for Evaluation of Medicinal Products (EMEA) 90
European Society for Pediatric Endocrinology 34
flatbush diabetes see ketosis-prone diabetes
fluid overload 25, 26, 145
fluid replacement in DKA 15, 17, 17, 41–2
children and adolescents 41–2, 43–4, 55
in HHS 71–2
free fatty acids 8, 72
Glasgow Coma Scale 38
glibenclamide 114, 115, 127–8
drug interactions 116
hypoglycemia caused by 115–16
prevalence 118, 119, 120
gliclazide 114, 128–9
drug interactions 116–17
hypoglycemia caused by 115–16
prevalence 120
glimepiride 79, 114, 115–16, 171, 172
drug interactions 116
hypoglycemia caused by 120
glipizide 114, 115
drug interactions 116
hypoglycemia caused by 118, 120
glutinides 149
glomerular filtration rate 137, 139
glucagon 33
in hypoglycemia response
type 1 diabetes 86
type 2 diabetes 121, 122
in hypoglycemia treatment 100–1, 126
glucagon-like 1 agonists 124
glucocorticoids 149, 158, 162, 170–1
gluconeogenesis 33, 135
glucose
  control of levels see glycemic control
  intravenous 101–2
  levels in DKA 2
  normalization of 98, 100–2
  see also hyperglycemia; hypoglycemia
glucose meters 98
glucose monitoring
  continuous 120
  in DKA 23–5, 24, 25
    children and adolescents 35, 40
  during illness 182
  in-hospital 148–55
  self-monitoring 98, 104
glucose regulation 85–7, 86
glucose tablets 100
glucose-insulin infusion 163–4
glucose-insulin-potassium infusion 164
glyburide see glibenclamide
glycemic control
  continuous glucose monitoring system 120
  in-hospital 148–51
  critically ill patients 151–5
  perioperative see perioperative hyperglycemia
poor 168–9
  self-monitoring 98, 104
glycemic threshold 87, 124
  for insulin administration 153–4
glycogenolysis 33
glycolysis 134, 135
growth hormone 33
hypoglycemia response
  type 1 diabetes 86
  type 2 diabetes 121
heart failure, metformin contraindicated in 139
hemodialysis, in lactic acidosis 142
HHS see hyperosmolar non-ketotic hyperglycemia
hydrocortisone 126
beta-hydroxy-butyrate 8, 11
hyperaldosteronism 74
hyperchloremic acidosis 25, 26, 42
hyperglycemia 28, 33, 37, 76
  complications 76
DKA 3, 7
  hyperosmolar non-ketotic 61–84
  in-hospital 148–77
    case studies 171–5
    causes 149
    critically ill patients 151–5
    glucocorticoid use 170–1
    insulin therapy 158–65, 159
    non-critically ill patients 155–6, 156
    oral antidiabetic agents 156–7
    outcomes 149–50
    total parenteral nutrition 170
    osmotic diuresis 7, 11–12
perioperative 165–6
  emergency surgery 170
  intraoperative management 169
  postoperative management 169, 173
  preoperative management 166–9, 167, 172–3
rebound 48
  see also diabetic ketoacidosis
hyperglycemic crisis 65, 77, 80
hyperglycemic decompensation 74
hyperlactemia 133
hyperosmolality 33
hyperosmolar non-ketotic
  hyperglycemia (HHS) 61–84, 178
  case studies 79–82
  causes 62–5
clinical management 69–75, 70
fluid replacement 71–2
insulin therapy 72–4
complications 76–7
cerebral edema 76–7
rhabdomyolysis 77
definition 61–2
diagnosis 65–9
laboratory evaluation 12, 67–9
epidemiology 62
follow-up 77–8
mental status in 66
patient advice 79
hypertonic saline, cerebral edema 50
hypoalbuminemia 11
hypochloremic acidosis
in DKA 12
non-anion gap 26, 27
hypoglycemia 25, 76
acute 96–7
asymptomatic 89–90, 98
blood glucose regulation 85–7, 86
case studies
type 1 diabetes 105–9
type 2 diabetes 127–30
chronic recurrent 97–8
clinical presentation 86, 92–4, 93, 94, 123–4, 124
autonomic symptoms 93
neuroglycopenia 93, 123
counter-regulatory response
type 1 diabetes 86, 87–9
type 2 diabetes 121–2, 124
dead-in-bed syndrome 96
definition of 85
insulin secretagogue-induced
113–32
prevalence 118–21, 119
risk factors 115–16
treatment 124–7, 125
insulin-induced 85–112
classification 89–90
consequences 96–8
management 98–105, 99
predisposing factors 94–6
prevalence 90–2, 119
moderate 90
mortality 126
relative 90
severe 89
follow-up 103
treatment 100
symptomatic
documented 89
probable 90
treatment
insulin secretagogue-induced hypoglycemia 124–7, 125
insulin-induced hypoglycemia 98–105, 99
unawareness 88–9, 122
glycemic thresholds 87, 124
hypoglycemia-associated autonomic failure (HAAF) 89, 104
hypoglycemic coma 126
hypoglycemic hemiplegia 96
hypokalemia 76
correction of see potassium, replacement
in DKA 12, 25, 46
in HHS 68–9
hyponatremia
correction of see sodium, replacement
in DKA 12
in HHS 66
hypophosphatemia, in DKA 12, 23
hypovolemia
in DKA 9
in HHS 66
hypovolemic shock 71
illness in diabetics 178–91
case studies 187–90
definition 178
diagnosis of problems 179–80
epidemiology 179
follow-up management 184–5
management 180–4, 181
patient advice 185–7
potential causes 179
sick-day rules 27, 29, 79, 183, 185–7
incretin mimetics 157
infections, increased susceptibility to 179
insulin 149
deficiency 33
in DKA 17–21
children and adolescents 42, 45–6, 56–7
during illness 180, 182, 183–4
in HHS 72–4, 77–8
human 150, 160
in-hospital hyperglycemia 150, 158–65, 159
basal requirements 159–60, 162–3, 163
critically ill patients 151–5
patients unable to eat 162–5, 163
patients who are eating 158–62, 162
prandial requirements 160–2, 162
infusion 164
rate adjustments 154
resistance 72
secretion
stimulation of see insulin secretagogues
suppression of 86
insulin aspart 155, 160
insulin detemir 155, 161
insulin glargine 105, 106, 155, 161, 172, 187
insulin glulisine 155, 160
insulin lispro 105–6, 155, 160, 187
insulin pump, and DKA 34–5
insulin secretagogues 113–18, 114
drug interactions 115–17, 129–30
hypoglycemia risk 115–16
in-hospital use 156–7
see also individual drugs
insulin secretagogue-induced hypoglycemia 113–32
prevalence 118–21, 119
risk factors 115–16
treatment 124–7, 125
see also hypoglycemia
insulin-induced hypoglycemia 85–112
classification 89–90
consequences 96–8
management 98–105, 99
predisposing factors 94–6
prevalence 90–2, 119
see also hypoglycemia
intensive care unit 150
International Society for Pediatric and Adolescent Diabetes 34
intravenous fluids 42
ketoacidosis
alcoholic 14
diabetic see diabetic ketoacidosis
ketogenesis 33
ketolysis 8
ketone bodies 8, 11, 30, 72
ketonemia 184
in DKA 2, 8, 33, 37
in HHS 61
ketones 8
serum 14, 16, 25
urine see ketonuria
ketonuria 182, 183, 184
in DKA 12–13, 16, 25, 37
ketosis 28, 30, 80, 155, 165, 169
pregnancy 14
starvation 14, 182
ketosis-prone diabetes 1, 3
Krebs cycle 135
Kussmaul respiration 9, 30, 37

lactate 133
  blood levels 140
  clearance 133
  hyperlactemia 133
  metabolism 134
lactate dehydrogenase 134
L-form 140
lactic acidosis 34, 133–47
  case studies 142–6
  causes 137, 138
  classification 136–40
    type A 136, 137
    type B 136–7, 138
  clinical presentation 136
D-form 139–40
  diagnosis 140–1
  drug-induced 138
  pathogenesis 135–6
  prevention 144, 145–6
  treatment 141–2
Lactobacillus acidophilus 140
Lawson Wilkins Society for Pediatric Endocrinology 34
leukocytosis, in DKA 12–13, 37, 68
linezolide, and lactic acidosis 140
lipase, in DKA 13, 68
lipolysis 8, 33

magnesium, in DKA 8, 12, 39, 40
magnesium in cerebral edema 50, 76–7
meglitinides 113–18, 114, 115
  hypoglycemia 120
mental status
  in DKA 2
  in HHS 66
metabolic acidosis
  anion gap 143–4
  in DKA 8, 28, 33, 37

Kussmaul respiration 9, 30, 37
management 21–2, 47
metformin 79, 171, 172
  contraindication in heart failure 139
  and lactic acidosis 137, 139, 141
miglitol 100
MRSA 140
nateglinide 113, 114, 115
  drug interactions 116–17
  hypoglycemia caused by 115–16
neuroglycopenia 93, 123
nocturnal enuresis 180
noradrenaline see norepinephrine
norepinephrine 33
  hypoglycemia response, type 2 diabetes 121
oral antidiabetic agents
  biguanides 137, 157
  in-hospital use 157–8
  incretin-based 157
  insulin secretagogues see insulin secretagogues
thiazolidinediones 157
see also individual drugs
osmolality
  in DKA 2, 13, 42
  effective 42
  in HHS 66
osmotic diuresis 7, 11–12, 149
see also electrolyte loss
oxidative phosphorylation 135
oxidative stress 149
pancreas
  alpha-cells 86
  beta-cells 86
paradoxical acidosis 22
patient advice
  in DKA 53–4
  in HHS 79
sick-day rules 185–7
perioperative hyperglycemia 165–6
case studies 171–5
emergency surgery 170
intraoperative management 169
postoperative management 169, 173
preoperative management 166–9, 167, 172–3
phenformin, and lactic acidosis 137
phosphate
losses 43
replacement
in DKA 23, 43
in HHS 75
6-phospho-fructokinase 135
phosphoenolpyruvate carboxykinase 135
plasminogen activator inhibitor I 77
polydipsia 180
in DKA 9, 29, 54
in HHS 65
polyuria 180
in DKA 9, 29, 54
in HHS 65
potassium
deficit see hypokalemia
losses 43
replacement
in DKA 22–3, 42, 43, 46–7
in HHS 74–5
pregnancy ketosis 14
propranolol, and hypoglycemia 129
pyruvate 133, 134
repaglinide 114, 115
drug interactions 116–17
hypoglycemia 115–16
rhabdomyolysis 27, 77
rhinocerebral mucormycosis 26
serum amylase see amylase
sick-day rules 27, 29, 79, 183, 185–7
see also illness in diabetics
sodium
deficit see hyponatremia
losses 43
replacement 43
starvation ketosis 14, 182
stress 72
sulfonylureas 113–18, 114, 149
hypoglycemia 115–16
prevalence 118, 119, 120
sulfonylurea receptor 113
thiazolidinediones 157
thrombosis 27
tolazamide 113, 114
tolbutamide 113, 114
total parenteral nutrition 170
urinary ketones see ketonuria
urinary tract infection 188–90
VADT trial 91
weight loss 180
in HHS 65
Whipple’s triad 85